217 related articles for article (PubMed ID: 34375305)
1. Bisphosphonates and breast cancer survival: a meta-analysis and trial sequential analysis of 81508 participants from 23 prospective epidemiological studies.
Liu Y; Zhao S; Zhang Y; Onwuka JU; Zhang Q; Liu X
Aging (Albany NY); 2021 Aug; 13(15):19835-19866. PubMed ID: 34375305
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates for breast cancer.
Pavlakis N; Stockler M
Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates in multiple myeloma: a network meta-analysis.
Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
[TBL] [Abstract][Full Text] [Related]
6. Effect of oral bisphosphonates for osteoporosis on development of skeletal metastases in women with breast cancer: results from a pharmaco-epidemiological study.
Kremer R; Gagnon B; Meguerditchian AN; Nadeau L; Mayo N
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25278509
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates for osteoporosis in primary biliary cirrhosis.
Rudic JS; Giljaca V; Krstic MN; Bjelakovic G; Gluud C
Cochrane Database Syst Rev; 2011 Dec; (12):CD009144. PubMed ID: 22161446
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates for Paget's disease of bone in adults.
Corral-Gudino L; Tan AJ; Del Pino-Montes J; Ralston SH
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD004956. PubMed ID: 29192423
[TBL] [Abstract][Full Text] [Related]
9. Clinical benefits of bone targeted agents in early breast cancer.
Coleman R
Breast; 2019 Nov; 48 Suppl 1():S92-S96. PubMed ID: 31839171
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonate and risk of cancer recurrence: protocol for a systematic review, meta-analysis and trial sequential analysis of randomised controlled trials.
Liu Y; Du C; Zhang Y; Zhao S; Zhao L; Li P; Hu F; Zhu L; Liu Y; Pang D; Zhao Y
BMJ Open; 2015 Apr; 5(4):e007215. PubMed ID: 25900461
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis.
Lopez-Olivo MA; Shah NA; Pratt G; Risser JM; Symanski E; Suarez-Almazor ME
Support Care Cancer; 2012 Nov; 20(11):2985-98. PubMed ID: 22956190
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis.
Ben-Aharon I; Vidal L; Rizel S; Yerushalmi R; Shpilberg O; Sulkes A; Stemmer SM
PLoS One; 2013; 8(8):e70044. PubMed ID: 23990894
[TBL] [Abstract][Full Text] [Related]
13. Osteoclast inhibitors to prevent bone metastases in men with high-risk, non-metastatic prostate cancer: A systematic review and meta-analysis.
Hayes AR; Brungs D; Pavlakis N
PLoS One; 2018; 13(1):e0191455. PubMed ID: 29370211
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates in adjuvant setting for breast cancer: a review of the meta-analysis of bisphosphonates' effects on breast cancer recurrence presented in December 2013 at San Antonio Breast Conference.
Costa L
Curr Opin Support Palliat Care; 2014 Dec; 8(4):414-9. PubMed ID: 25319273
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonates for periprosthetic bone loss after joint arthroplasty: a meta-analysis of 14 randomized controlled trials.
Lin T; Yan SG; Cai XZ; Ying ZM
Osteoporos Int; 2012 Jun; 23(6):1823-34. PubMed ID: 21932113
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant bisphosphonates or RANK-ligand inhibitors for patients with breast cancer and bone metastases: A systematic review and network meta-analysis.
Tesfamariam Y; Jakob T; Wöckel A; Adams A; Weigl A; Monsef I; Kuhr K; Skoetz N
Crit Rev Oncol Hematol; 2019 May; 137():1-8. PubMed ID: 31014505
[TBL] [Abstract][Full Text] [Related]
17. Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease? A meta-analysis of randomized controlled trials.
Mauri D; Valachis A; Polyzos NP; Tsali L; Mavroudis D; Georgoulias V; Casazza G
J Natl Compr Canc Netw; 2010 Mar; 8(3):279-86. PubMed ID: 20202461
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates for advanced prostate cancer.
Yuen KK; Shelley M; Sze WM; Wilt T; Mason MD
Cochrane Database Syst Rev; 2006 Oct; (4):CD006250. PubMed ID: 17054286
[TBL] [Abstract][Full Text] [Related]
19. [Biphosphonates in breast cancer--based on a Cochrane meta-analysis].
Junker N; Nielsen DL; Kamby C
Ugeskr Laeger; 2007 Sep; 169(37):3108-11. PubMed ID: 17877961
[No Abstract] [Full Text] [Related]
20. The role of bisphosphonates in early breast cancer.
Paterson AH
Oncologist; 2006; 11 Suppl 1():13-9. PubMed ID: 16971735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
